👋 Good morning! On some level, this was inevitable. The ultimate power couple, if you will.

The first pharma company to cross a $1 trillion valuation just partnered with the chipmaker that rode AI mania to $5 trillion. On Friday, Eli Lilly unveiled “LillyPod,” its Nvidia-powered supercomputer that executives say may be the most powerful in pharma.

The mission? Escape pharma’s boom-and-bust cycle. The decade of R&D, the patent cliff, the revenue peak, then the slow descent. Lilly, currently riding tirzepatide to historic highs, would prefer to skip the trough.

But before you assume three-month drug development timelines, Lilly is pumping the brakes. Leadership has warned that AI hype is “damaging and destructive.” The goal isn’t science fiction. It’s cutting timelines from 10 years to 5.

Manufacturing may be where the real impact lands. AI already touches much of Lilly’s production network, and each LillyPod GPU reportedly dwarfs 1990s supercomputers in raw power.

So is this structural reinvention or investor-friendly optics?

Probably both.

Lilly has cash. Nvidia has chips. Investors want AI. Biology is still hard. Whether LillyPod becomes pharma’s engine of reinvention, or its most expensive lab accessory, remains to be seen.

Either way, the patent cliff now has a GPU problem.

⚖️ FDA’s Prasad Under Internal Probe
FDA leadership has reportedly enlisted outside investigators to examine complaints that CBER Director Vinay Prasad fostered a toxic workplace and retaliated against dissenting reviewers. HHS dismissed the reports as part of a PR campaign, while Commissioner Marty Makary publicly praised Prasad as a “genius.” The twist? Prasad was briefly dismissed last year before being reinstated days later. Washington drama, biotech edition.

🏆 BMS’ $800M ADC Bet Delivers in Phase 3
Bristol Myers Squibb’s EGFR×HER3 bispecific ADC izalontamab brengitecan hit dual primary survival endpoints in a phase 3 trial for previously treated triple-negative breast cancer. The drug came via an $800 million upfront deal with China’s SystImmune in 2023, marking BMS’ formal entry into the ADC race. With multiple late-stage wins now logged in China, the asset looks increasingly validated. For BMS, the China-to-global licensing play is aging well.

💵 Boehringer’s $500M Autoimmune Swing
Boehringer Ingelheim inked a deal worth over $500 million with UK biotech Sitryx for a preclinical oral small molecule program targeting immune cell metabolism. The pitch is precision immunology without injectables. If successful, it could open a new oral lane in autoimmune disease. If not, it joins the crowded “promising but early” pile.

🇯🇵 Asahi Kasei Buys Antiviral Arsenal for $920M
Japan’s Asahi Kasei is acquiring Germany’s Aicuris for roughly $920 million, adding approved and investigational antivirals focused on immunocompromised patients. The portfolio includes a phase 3-ready herpes simplex therapy and a BK virus candidate for kidney transplant patients. Asahi’s U.S. subsidiary, Veloxis, will execute the deal. Transplant medicine just got a deeper bench.

🏭 Novo Doubles Down on Oral GLP-1. Novo Nordisk is investing €432 million ($506 million) in Ireland to expand oral GLP-1 manufacturing capacity and reinforce supply outside the U.S.

👨‍💼 Sarepta CEO to Step Down. Doug Ingram will retire by the end of 2026 after a decade marked by Duchenne breakthroughs and controversy.

🤝 Earendil’s $885M ADC Pact. Earendil Labs secured exclusive rights to WuXi XDC’s linker-payload platform in a deal worth up to $885 million to build next-gen ADCs.

💉 Moderna Wins EU Combo Nod. Europe’s CHMP recommended approval of Moderna’s COVID-flu combo shot for adults 50+, the first of its kind.

❌ Viatris Cuts 10%. The company will slash about 10% of its workforce over three years in a restructuring aimed at saving up to $700 million annually.

🫁 Boehringer’s Lung Cancer Speed Run. Hernexeos scored first-line FDA approval via the agency’s National Priority Voucher pilot program.

👁️ Vyvgart Eyes New Indication. Argenx reported phase 3 success in ocular myasthenia gravis as Vyvgart sales continue climbing.

📈 Bimzelx Goes Blockbuster. UCB’s immunology star jumped from €607M ($711M) in 2024 sales to €2.22B ($2.6B) in 2025.

At a Senate hearing last week, one neurologist described meetings with the FDA as “like talking to a brick wall.”

That wall has a name: rare disease review.

Physicians, biotech CEOs and patient advocates testified that the agency has grown hesitant to use the regulatory flexibility Congress designed for rare diseases. Accelerated approvals. Real-world evidence. External controls. Tools meant for urgency.

Biohaven’s rejected ataxia drug became the flashpoint. After missing its first phase 3, the company regrouped with real-world data and won priority review. Then came a complete response letter. Now, 300 patients stable on the drug may lose access.

FDA leadership argues it remains committed to rigorous science. Commissioner Marty Makary defended the agency publicly and cautioned against approving therapies without clear benefit. Meanwhile, rare disease advocates say advisory committee meetings have plummeted and regulatory reversals are rising.

The tension is philosophical.

How much uncertainty is acceptable when patients have no alternatives? How flexible should regulators be when diseases are ultrarare and trials are messy by necessity?

Roughly 1 in 10 Americans lives with a rare disease. For many, five to eight years for another placebo-controlled trial is not just slow. It is existential.

In biotech, timelines are strategy. In rare disease, they are lifespans.

Right now, Capitol Hill is asking whether the FDA’s risk tolerance has quietly shifted. And patients are asking whether flexibility written into law is still being used in practice.

That is how much Generate: Biomedicines just raised in its IPO, the largest biotech debut since 2024. The Flagship-founded company priced 25 million shares at $16 apiece, with another $60 million potentially on deck if underwriters exercise their option. After a two-year IPO drought, the biotech window is not just cracked open. It is creaking wider.

Here’s what biotech Redditors are talking about:

🤔 Bonus for Quick FDA Reviews? What Could Go Wrong.
Reddit lit up over the FDA’s proposal to offer bonuses for speedy drug reviews. Top comment energy: “People wouldn’t possibly rush decisions for money… right?” Jokes flew about reviewers checking every box just to finance a backyard pool. Others speculated this is a stepping stone toward AI-assisted reviews. Faster? Definitely. Risk-free? The internet remains unconvinced.

🤩 Lilly’s AI Glow-Up.
Biotech Reddit had mixed feelings about Lilly’s Nvidia supercomputer flex. Some called it visionary. Others called it optics. A common theme emerged: pharma is not compute-limited, it is biology-limited. Still, in a market that rewards AI narratives, Lilly may be playing the sentiment game as much as the science one.

💊 MDMA’s Risky Comeback. AtaiBeckley’s R-MDMA reduced anxiety in phase 2a, but shares slid as investors debated the risk-reward math.

🏃 FDA Floats Speed Bonuses. The agency is piloting bonus pay for reviewers who complete regulatory work ahead of schedule.

🏭 Merck Winds Down Gardasil Output. The company will lay off over 150 workers at its North Carolina plant amid falling global vaccine demand.

💗 Atrium Launches With $270M and a Cardio RNA Mission
Fresh off Novartis’ $12B Avidity acquisition, Atrium Therapeutics has spun out with $270 million and two preclinical siRNA programs targeting rare genetic cardiomyopathies. ATR 1072 aims at PRKAG2 syndrome, while ATR 1086 tackles PLN cardiomyopathy. Phase 1 for the lead candidate is slated for later this year. Same RNA roots. New ticker. Fresh runway.

🧬 March 3, 1918 — Arthur Kornberg Is Born.
The future Nobel laureate would go on to discover the mechanisms behind DNA and RNA synthesis, laying the biochemical foundation for modern molecular biology. Sometimes the most powerful tools in biotech start with understanding how the code itself is written.

Maybe LillyPod becomes pharma’s reinvention engine. Maybe it’s just a very expensive lab accessory. Either way, the IT department is now invited to pipeline meetings.

That’s all for today. See you Thursday. 👋
Don’t forget to update your software. If you work at Lilly, your pipeline might depend on it.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead